Gene transfer of human Apoe isoforms results in differential modulation of amyloid deposition and neurotoxicity in mouse brain

Science Translational Medicine

Volumn 5, Issue 212, 2013, Pages

  Hudry, Eloise ^a   Dashkoff, Jonathan ^a   Roe, Alysson D ^a   Takeda, Shuko ^a   Koffie, Robert M ^a   Hashimoto, Tadafumi ^a   Scheel, Maria ^b   Spires Jones, Tara ^a   Arbel Ornath, Michal ^a   Betensky, Rebecca ^c   Davidson, Beverly L ^b   Hyman, Bradley T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E4; PARVOVIRUS VECTOR;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; GENE TRANSFER; GENETIC RISK; INTERSTITIAL FLUID; MICRODIALYSIS; MOUSE; MULTIPHOTON MICROSCOPY; NEURITE; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; SYNAPSE; TOMOGRAPHY; TRANSGENIC MOUSE;

AMYLOID; ANIMALS; APOLIPOPROTEINS E; BRAIN; HUMANS; INJECTIONS, INTRAVENTRICULAR; MICE; MICE, TRANSGENIC; TRANSFECTION;

EID: 84890365334     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007000     Document Type: Article

References (53)

1. E. H. Corder, A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, M. A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923 (1993).
2. W. J. Strittmatter, A. D. Roses, Apolipoprotein E and Alzheimer's disease. Annu. Rev. Neurosci. 19, 53-77 (1996).
3. H. L. West, G. W. Rebeck, B. T. Hyman, Frequency of the apolipoprotein E epsilon 2 allele is diminished in sporadic Alzheimer disease. Neurosci. Lett. 175, 46-48 (1994).
4. D. J. Selkoe, The molecular pathology of Alzheimer's disease. Neuron 6, 487-498 (1991).
5. D. J. Selkoe, Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81, 741-766 (2001).
6. G. W. Rebeck, J. S. Reiter, D. K. Strickland, B. T. Hyman, Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11, 575-580 (1993).
7. A. M. Fagan, M. Watson, M. Parsadanian, K. R. Bales, S. M. Paul, D. M. Holtzman, Human and murine ApoE markedly alters Aβ metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9, 305-318 (2002).
8. R. M. Koffie, T. Hashimoto, H. C. Tai, K. R. Kay, A. Serrano-Pozo, D. Joyner, S. Hou, K. J. Kopeikina, M. P. Frosch, V. M. Lee, D. M. Holtzman, B. T. Hyman, T. L. Spires-Jones, Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain 135, 2155-2168 (2012).
9. R. D. Bell, E. A. Winkler, I. Singh, A. P. Sagare, R. Deane, Z. Wu, D. M. Holtzman, C. Betsholtz, A. Armulik, J. Sallstrom, B. C. Berk, B. V. Zlokovic, Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 485, 512-516 (2012).
10. J. M. Castellano, J. Kim, F. R. Stewart, H. Jiang, R. B. DeMattos, B. W. Patterson, A. M. Fagan, J. C. Morris, K. G. Mawuenyega, C. Cruchaga, A. M. Goate, K. R. Bales, S. M. Paul, R. J. Bateman, D. M. Holtzman, Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).
11. S. B. Dumanis, J. A. Tesoriero, L. W. Babus, M. T. Nguyen, J. H. Trotter, M. J. Ladu, E. J. Weeber, R. S. Turner, B. Xu, G. W. Rebeck, H. S. Hoe, ApoE4 decreases spine density and dendritic complexity in cortical neurons in vivo. J. Neurosci. 29, 15317-15322 (2009).
12. D. M. Holtzman, A. M. Fagan, Potential role of apoE in structural plasticity in the nervous system; implications for disorders of the central nervous system. Trends Cardiovasc. Med. 8, 250-255 (1998).
13. P. E. Cramer, J. R. Cirrito, D. W. Wesson, C. Y. Lee, J. C. Karlo, A. E. Zinn, B. T. Casali, J. L. Restivo, W. D. Goebel, M. J. James, K. R. Brunden, D. A. Wilson, G. E. Landreth, ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503-1506 (2012).
14. G. Liu, I. H. Martins, J. A. Chiorini, B. L. Davidson, Adeno-associated virus type 4 (AAV4) targets ependyma and astrocytes in the subventricular zone and RMS. Gene Ther. 12, 1503-1508 (2005).
15. R. E. Pitas, J. K. Boyles, S. H. Lee, D. Foss, R. W. Mahley, Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148-161 (1987).
16. T. Wisniewski, B. Frangione, Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135, 235-238 (1992).
17. S. Takeda, N. Sato, K. Ikimura, H. Nishino, H. Rakugi, R. Morishita, Novel microdialysis method to assess neuropeptides and large molecules in free-moving mouse. Neuroscience 186, 110-119 (2011).
18. J. R. Cirrito, P. C. May, M. A. O'Dell, J. W. Taylor, M. Parsadanian, J. W. Cramer, J. E. Audia, J. S. Nissen, K. R. Bales, S. M. Paul, R. B. DeMattos, D. M. Holtzman, In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J. Neurosci. 23, 8844-8853 (2003).
19. G. Liu, I. Martins, J. A. Wemmie, J. A. Chiorini, B. L. Davidson, Functional correction of CNS phenotypes in a lysosomal storage disease model using adeno-associated virus type 4 vectors. J. Neurosci. 25, 9321-9327 (2005).
20. C. Bachmeier, D. Beaulieu-Abdelahad, F. Crawford, M. Mullan, D. Paris, Stimulation of the retinoid x receptor facilitates beta-amyloid clearance across the blood-brain barrier. J. Mol. Neurosci. 49, 270-276 (2013).
21. R. Deane, A. Sagare, K. Hamm, M. Parisi, S. Lane, M. B. Finn, D. M. Holtzman, B. V. Zlokovic, apoE isoform-specific disruption of amyloid β peptide clearance from mouse brain. J. Clin. Invest. 118, 4002-4013 (2008).
22. S. M. Greenberg, G. W. Rebeck, J. P. Vonsattel, T. Gomez-Isla, B. T. Hyman, Apolipoprotein E ε4 and cerebral hemorrhage associated with amyloid angiopathy. Ann. Neurol. 38, 254-259 (1995).
23. L. Cruz, B. Urbanc, S. V. Buldyrev, R. Christie, T. Gómez-Isla, S. Havlin, M. McNamara, H. E. Stanley, B. T. Hyman, Aggregation and disaggregation of senile plaques in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 94, 7612-7616 (1997).
24. R. D. Terry, E. Masliah, D. P. Salmon, N. Butters, R. DeTeresa, R. Hill, L. A. Hansen, R. Katzman, Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572-580 (1991).
25. S. T. DeKosky, S. W. Scheff, S. D. Styren, Structural correlates of cognition in dementia: Quantification and assessment of synapse change. Neurodegeneration 5, 417-421 (1996).
26. T. Hashimoto, A. Serrano-Pozo, Y. Hori, K. W. Adams, S. Takeda, A. O. Banerji, A. Mitani, D. Joyner, D. H. Thyssen, B. J. Bacskai, M. P. Frosch, T. L. Spires-Jones, M. B. Finn, D. M. Holtzman, B. T. Hyman, Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J. Neurosci. 32, 15181-15192 (2012).
27. A. Sen, D. L. Alkon, T. J. Nelson, Apolipoprotein E3 (ApoE3) but not ApoE4 protects against synaptic loss through increased expression of protein kinase Cε. J. Biol. Chem. 287, 15947-15958 (2012).
28. K. D. Micheva, S. J. Smith, Array tomography: A new tool for imaging the molecular architecture and ultrastructure of neural circuits. Neuron 55, 25-36 (2007).
29. R. M. Koffie, M. Meyer-Luehmann, T. Hashimoto, K. W. Adams, M. L. Mielke, M. Garcia-Alloza, K. D. Micheva, S. J. Smith, M. L. Kim, V. M. Lee, B. T. Hyman, T. L. Spires-Jones, Oligomeric amyloid β associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc. Natl. Acad. Sci. U.S.A. 106, 4012-4017 (2009).
30. T. L. Spires, M. Meyer-Luehmann, E. A. Stern, P. J. McLean, J. Skoch, P. T. Nguyen, B. J. Bacskai, B. T. Hyman, Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278-7287 (2005).
31. G. M. Shankar, B. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe, B. L. Sabatini, Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866-2875 (2007).
32. H. Y. Wu, E. Hudry, T. Hashimoto, K. Kuchibhotla, A. Rozkalne, Z. Fan, T. Spires-Jones, H. Xie, M. Arbel-Ornath, C. L. Grosskreutz, B. J. Bacskai, B. T. Hyman, Amyloid β induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J. Neurosci. 30, 2636-2649 (2010).
33. D. M. Holtzman, K. R. Bales, T. Tenkova, A. M. Fagan, M. Parsadanian, L. J. Sartorius, B. Mackey, J. Olney, D. McKeel, D. Wozniak, S. M. Paul, Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 2892-2897 (2000).
34. V717F transgenic mice. Acta Neuropathol. 100, 451-458 (2000).
35. A. D. Roses, An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch. Neurol. 67, 536-541 (2010).
36. K. L. Youmans, L. M. Tai, E. Nwabuisi-Heath, L. Jungbauer, T. Kanekiyo, M. Gan, J. Kim, W. A. Eimer, S. Estus, G. W. Rebeck, E. J. Weeber, G. Bu, C. Yu, M. J. Ladu, APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J. Biol. Chem. 287, 41774-41786 (2012).
37. Q. Jiang, C. Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, K. Mann, B. Lamb, T. M. Willson, J. L. Collins, J. C. Richardson, J. D. Smith, T. A. Comery, D. Riddell, D. M. Holtzman, P. Tontonoz, G. E. Landreth, ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681-693 (2008).
38. J. Kim, H. Jiang, S. Park, A. E. Eltorai, F. R. Stewart, H. Yoon, J. M. Basak, M. B. Finn, D. M. Holtzman, Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J. Neurosci. 31, 18007-18012 (2011).
39. R. B. DeMattos, Apolipoprotein E dose-dependent modulation of β-amyloid deposition in a transgenic mouse model of Alzheimer's disease. J. Mol. Neurosci. 23, 255-262 (2004).
40. A. Iwata, K. D. Browne, X. H. Chen, T. Yuguchi, D. H. Smith, Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats. J. Neurosci. Res. 82, 103-114 (2005).
41. K. J. Page, R. D. Hollister, B. T. Hyman, Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: An in situ hybridization study. Neuroscience 85, 1161-1171 (1998).
42. N. Srivastava, M. Averna, R. A. Srivastava, Dietary cholesterol and estrogen administration elevate brain apolipoprotein E in mice by different mechanisms. Indian J. Biochem. Biophys. 45, 410-415 (2008).
43. L. M. Bekris, N. M. Galloway, T. J. Montine, G. D. Schellenberg, C. E. Yu, APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am. J. Med. Genet. B Neuropsychiatr. Genet. 153B, 409-417 (2010).
44. J. C. Dodart, R. A. Marr, M. Koistinaho, B. M. Gregersen, S. Malkani, I. M. Verma, S. M. Paul, Gene delivery of human apolipoprotein E alters brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 102, 1211-1216 (2005).
45. E. Hudry, D. Van Dam, W. Kulik, P. P. De Deyn, F. S. Stet, O. Ahouansou, A. Benraiss, A. Delacourte, P. Bougnères, P. Aubourg, N. Cartier, Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after the onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Ther. 18, 44-53 (2010).
46. J. Kim, J. M. Castellano, H. Jiang, J. M. Basak, M. Parsadanian, V. Pham, S. M. Mason, S. M. Paul, D. M. Holtzman, Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular Aβ clearance. Neuron 64, 632-644 (2009).
47. M. A. Kuszczyk, S. Sanchez, J. Pankiewicz, J. Kim, M. Duszczyk, M. Guridi, A. A. Asuni, P. M. Sullivan, D. M. Holtzman, M. J. Sadowski, Blocking the interaction between apolipoprotein E and Aβ reduces intraneuronal accumulation of Aβ and inhibits synaptic degeneration. Am. J. Pathol. 182, 1750-1768 (2013).
48. J. Brodbeck, J. McGuire, Z. Liu, A. Meyer-Franke, M. E. Balestra, D. E. Jeong, M. Pleiss, C. McComas, F. Hess, D. Witter, S. Peterson, M. Childers, M. Goulet, N. Liverton, R. Hargreaves, S. Freedman, K. H. Weisgraber, R. W. Mahley, Y. Huang, Structure-dependent impairment of intracellular apolipoprotein E4 trafficking and its detrimental effects are rescued by small-molecule structure correctors. J. Biol. Chem. 286, 17217-17226 (2011).
49. D. R. Borchelt, T. Ratovitski, J. van Lare, M. K. Lee, V. Gonzales, N. A. Jenkins, N. G. Copeland, D. L. Price, S. S. Sisodia, Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 19, 939-945 (1997).
50. K. Hsiao, P. Chapman, S. Nilsen, C. Eckman, Y. Harigaya, S. Younkin, F. Yang, G. Cole, Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102 (1996).
51. B. J. Bacskai, W. E. Klunk, C. A. Mathis, B. T. Hyman, Imaging amyloid-β deposits in vivo. J. Cereb. Blood Flow Metab. 22, 1035-1041 (2002).
52. E. B. Lee, L. Z. Leng, B. Zhang, L. Kwong, J. Q. Trojanowski, T. Abel, V. M. Lee, Targeting amyloid-β peptide (Aβ) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Aβ precursor protein (APP) transgenic mice. J. Biol. Chem. 281, 4292-4299 (2006).
53. W. Xia, T. Yang, G. Shankar, I. M. Smith, Y. Shen, D. M. Walsh, D. J. Selkoe, A specific enzyme-linked immunosorbent assay for measuring β-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease. Arch. Neurol. 66, 190-199 (2009).